STOCK TITAN

Alterity Therapeutics Ltd - ATHE STOCK NEWS

Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.

Alterity Therapeutics Ltd (ATHE) is a clinical-stage biotechnology company pioneering treatments for neurodegenerative disorders including Parkinson's and Alzheimer's diseases. This page serves as the definitive source for verified updates on the company's therapeutic developments, research milestones, and strategic initiatives.

Investors and researchers will find timely updates on ATH434 clinical trials, partnership announcements with leading medical institutions, and regulatory progress for novel drug candidates. Our curated news collection provides essential context for understanding Alterity's approach to targeting iron dysregulation in neurological conditions and its broader research pipeline.

Key content includes updates on:
- Phase I/II clinical trial results
- Collaborative research initiatives
- Peer-reviewed study publications
- Regulatory pathway developments
- Scientific conference presentations

Bookmark this page for structured access to Alterity Therapeutics' latest advancements in neuroprotective therapies. Check regularly for objective reporting on the company's progress in addressing complex neurodegenerative challenges through innovative biomedical research.

Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE) announced participation in two upcoming virtual investor events. CEO David Stamler will speak at the MST Financial Lifesciences & Biotech Forum on November 24, 2021, at 5:20 p.m. PST, and the Benchmark Company Discovery Conference on December 2, 2021. These events aim to highlight Alterity's innovative treatments for neurodegenerative diseases, particularly their lead asset, ATH434, targeting Parkinsonian disorders. For further details, visit www.alteritytherapeutics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
conferences
-
Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced its presentation at the American Autonomic Society's 32nd Annual International Symposium. The poster detailed findings from a Phase 1 trial of ATH434, a novel treatment for neurodegenerative conditions. The trial showed ATH434 was well tolerated with no cardiac adverse events and demonstrated favorable pharmacokinetics. The company plans to initiate a Phase 2 trial for Multiple System Atrophy in Q1 2022. ATH434 has received Orphan designation from the FDA and European Commission, supporting its potential in treating MSA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the publication of two preclinical studies supporting the use of ATH434 in treating Parkinsonian disorders. The studies, published in Journal of Parkinson's Disease and Plos One, highlight ATH434's potential in alleviating gastrointestinal complications and reducing alpha-synuclein aggregation—key factors in Parkinson's disease. ATH434, well-tolerated in Phase 1 trials, has received Orphan designation for treating Multiple System Atrophy. Further research is ongoing to advance this candidate into proof-of-concept studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE) announced two new preclinical studies showcasing the efficacy of ATH434 in treating Parkinsonian disorders. These studies published in the Journal of Parkinson's Disease and Plos One highlight the potential of ATH434 to alleviate gastrointestinal complications associated with Parkinson's disease by reversing colonic dysfunction and modulating iron trafficking. CEO David Stamler emphasized ATH434's promise in enhancing patient quality of life and mentioned ongoing preclinical studies aimed at advancing its clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) provided an update on its clinical programs and financials for Q1 FY22, ending September 30, 2021. The company reported a cash balance of A$41.3M and a quarterly cash outflow of A$4.9M, consistent with ongoing clinical activities. Key highlights include advancements in the ATH434 Phase 2 trial for Multiple System Atrophy (MSA) and the expansion of its bioMUSE study, which aims to refine patient selection for therapies. Intellectual property have seen significant growth, enhancing future opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced an expansion of the Phase 2 clinical trial for ATH434 targeting Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The double-blind, placebo-controlled study will assess ATH434's effects on biomarkers related to α-synuclein aggregation and iron levels over 12 months across 30 sites in Australia, New Zealand, Europe, and the U.S. Additionally, the bioMUSE study will expand to 20 patients, enhancing data for the trial. ATH434 has Orphan designation and aims to improve the quality of life for MSA patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE) reported progress in its biomarker study, bioMUSE, for early Multiple System Atrophy (MSA) patients. Data presented at the International Parkinson and Movement Disorder Society Congress 2021 highlighted the identification of iron accumulation in the brain as a potential biomarker for MSA. This could enhance patient selection for the upcoming Phase 2 trial of ATH434, aimed at treating MSA. The ongoing study is vital for understanding disease progression in MSA, which currently has no approved therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a Notice of Allowance from the USPTO for its patent application No. 17/239,375, securing exclusivity for a new group of iron chaperones aimed at addressing neurodegenerative diseases like Alzheimer's and Parkinson's. This patent covers over 80 novel compounds and follows the recent grant of another patent for 150 additional compounds. The company plans to advance its lead clinical asset, ATH434, into a Phase 2 trial, targeting Multiple System Atrophy and other conditions, while benefiting from approximately 20 years of patent exclusivity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.87%
Tags
none
-
Rhea-AI Summary

Alterity Therapeutics reported positive guidance from the European Medicines Agency for its ATH434 Phase 2 clinical trial in treating Multiple System Atrophy (MSA). During Q4 FY21, the company ended with a cash balance of A$28M, bolstered by $17M proceeds from an equity facility. An independent study published in Movement Disorders confirmed ATH434's neuroprotective effects in MSA models. The company aims to commence its clinical trial by year-end 2021, following progress in its natural history study underway at Vanderbilt University.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced study results showing that ATH434 can reduce α–synuclein related neurodegeneration in a murine model of Multiple System Atrophy (MSA). Published in Movement Disorders, the study found that ATH434 preserves neurons and enhances motor functions. The company plans to initiate a Phase 2 clinical trial by year-end. MSA, affecting about 15,000 patients in the U.S., currently has no approved therapy, making ATH434 a potential breakthrough treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
none
Alterity Therapeutics Ltd

Nasdaq:ATHE

ATHE Rankings

ATHE Stock Data

51.81M
15.21M
1.13%
0.95%
Biotechnology
Healthcare
Link
Australia
Melbourne